Grace Therapeutics, Inc.
GRCE· Nasdaq
GRCEGrace Therapeutics, Inc.
Filed Aug 13, 2020 · 10-Q · 44 days after period end · 0001171843-20-005901
| Metric | Q1 2021 | Q1 2020 |
|---|---|---|
| Net Income | -$4.67M | -$8.85M |
| EPS Diluted | -$0.05 | -$0.11 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Grace Therapeutics, Inc. · CIK 1444192 · Engraved from SEC EDGAR
ended Jun 30, 2020 · filed Aug 13, 2020 · 44 d after period end
